Epitel Raises $26 Million in Series B Funding
Epitel, a Salt Lake City-based healthcare technology company, has announced the successful closure of a $26 million Series B funding round. The round was led by Catalyst Health Ventures and Genoa Ventures. Epitel specializes in developing the REMI Remote EEG Monitoring System, a wireless EEG monitoring system designed for use in both healthcare facilities and at home. This innovative system aims to improve patient monitoring by providing flexible and accessible EEG data collection.
Leadership and Vision
The company is led by CEO Steven Pacelli, who expressed optimism about the impact this funding will have on the company's growth and development. "This investment will allow us to expand our capabilities and reach more patients who can benefit from our technology," Pacelli stated.
Strategic Use of Funds
While specific plans for the Series B funding were not detailed, companies in similar stages typically use such funds to enhance product development, expand market reach, and increase operational capacity. Given Epitel's focus on wireless EEG monitoring, it is likely that the investment will support advancements in their technology and potentially broaden their market presence.
Lead Investors
The Series B round was spearheaded by Catalyst Health Ventures and Genoa Ventures. These investors are known for their focus on healthcare innovations, indicating a strong alignment with Epitel’s mission to advance healthcare monitoring technologies.
Location and Impact
Situated in Salt Lake City, Utah, Epitel is well-positioned in a growing tech hub with access to both talent and resources that can drive further innovation in the medical technology space. The region has seen a rise in healthcare technology advancements, and Epitel's latest funding round is a testament to the area's potential.
In conclusion, Epitel's $26 million Series B funding round marks a significant milestone for the company as it continues to develop and expand its wireless EEG monitoring solutions. The involvement of prominent investors like Catalyst Health Ventures and Genoa Ventures highlights the confidence in Epitel's vision and potential impact on the healthcare industry.